Biotricity (NASDAQ:BTCY) & Accuray (NASDAQ:ARAY) Critical Contrast

Accuray (NASDAQ:ARAY) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Risk and Volatility

Accuray has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Institutional and Insider Ownership

64.1% of Accuray shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 4.2% of Accuray shares are held by company insiders. Comparatively, 10.1% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Accuray and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Accuray	-0.96%	-9.75%	-0.93%
Biotricity	-80.42%	N/A	-188.47%

Valuation & Earnings

This table compares Accuray and Biotricity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$453.14 million	0.41	-$15.55 million	($0.05)	-36.40
Biotricity	$12.06 million	0.86	-$14.09 million	($1.08)	-0.39

Biotricity has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Accuray and Biotricity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	0	0	0	0	0.00
Biotricity	0	1	0	0	2.00

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.